Loading company…
SalioGen develops non-viral genetic medicines for inherited disorders.
Founded in 2020 and based in Massachusetts, SalioGen is developing Gene Coding, a genetic medicine platform using Exact DNA Integration Technology for non-viral gene therapy. In January 2022, it raised USD 115 million in Series B funding co-led by EPIQ Capital Group and GordonMD Global Investments. The funding was intended to grow the team, build manufacturing and automation capabilities, and advance preclinical programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in